Astrazeneca Pharma to shut R&D site in Bangalore: Report

30 Jan 2014 Evaluate

Astrazeneca Pharma India is reportedly planning to close its Avishkar research and development (R&D) site in Bangalore later this year. The decision is part of the company’s broader global business strategy to simplify its research and development footprint and focus resources on three core therapy areas such as oncology, cardiovascular and metabolic diseases, and respiratory, inflammation and autoimmunity.

The site was working on pharmaceutical development projects and it will no longer carry out early stage research into neglected tropical diseases, TB and malaria.

Astrazeneca Pharma India is engaged in the business of manufacturing and marketing pharmaceutical products in healthcare segments namely gastrointestinal, cardiovascular, cancer, respiratory, neurosciences and infection.

 

Astrazeneca Pharma I Share Price

6336.90 48.00 (0.76%)
22-Nov-2024 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1797.80
Dr. Reddys Lab 1213.90
Cipla 1486.30
Lupin 2069.95
Zydus Lifesciences 948.70
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.